Pneumonia endpoints must be standardized for adult pneumococcal vaccine trials

Motoi Suzuki¹, Konosuke Morimoto²

Affiliations

¹ Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan. Electronic address: mosuzuki@niid.go.jp.
² Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.

PMID: 31615716
DOI: 10.1016/j.vaccine.2019.10.013

Comment

Pneumonia endpoints must be standardized for adult pneumococcal vaccine trials

Motoi Suzuki et al. Vaccine. 2020.

. 2020 Dec 14;38(52):8259.

doi: 10.1016/j.vaccine.2019.10.013. Epub 2019 Oct 12.

Authors

Motoi Suzuki¹, Konosuke Morimoto²

Affiliations

¹ Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan. Electronic address: mosuzuki@niid.go.jp.
² Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.

PMID: 31615716
DOI: 10.1016/j.vaccine.2019.10.013

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Comment on

Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial.
Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D'Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, Takei Y, Gabazza EC. Maruyama T, et al. BMJ. 2010 Mar 8;340:c1004. doi: 10.1136/bmj.c1004. BMJ. 2010. PMID: 20211953 Free PMC article. Clinical Trial.
Rethinking results from the Japanese 23-valent pneumococcal polysaccharide vaccine randomized clinical trial.
Gessner BD, Theilacker C, Jodar L. Gessner BD, et al. Vaccine. 2019 Aug 14;37(35):4853-4857. doi: 10.1016/j.vaccine.2019.07.040. Epub 2019 Jul 18. Vaccine. 2019. PMID: 31327653

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pneumonia endpoints must be standardized for adult pneumococcal vaccine trials

Affiliations

Pneumonia endpoints must be standardized for adult pneumococcal vaccine trials

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical